Phathom Pharmaceuticals, Inc.

NasdaqGS:PHAT Stock Report

Market Cap: US$1.2b

Phathom Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:PHAT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
03 Nov 25SellUS$7,079Robert BreedloveIndividual524US$13.51
05 Sep 25SellUS$5,573Robert BreedloveIndividual461US$12.09
16 Jul 25SellUS$14,152Robert BreedloveIndividual1,692US$8.36
21 May 25BuyUS$14,609Frazier Life Sciences Management, LPCompany3,780US$3.86
14 May 25BuyUS$24,462Frazier Life Sciences Management, LPCompany7,420US$3.32
12 May 25BuyUS$152,917Frazier Life Sciences Management, LPCompany48,203US$3.62
12 May 25BuyUS$5,938,596Frazier Life Sciences Management, LPCompany1,864,577US$3.24
07 May 25BuyUS$24,985Asit ParikhIndividual10,000US$2.60
07 Apr 25SellUS$16,740Molly HendersonIndividual3,678US$4.55
13 Mar 25BuyUS$44,200Asit ParikhIndividual10,000US$4.42
21 Jan 25SellUS$125,884Terrie CurranIndividual19,109US$6.59
21 Jan 25SellUS$51,957Azmi NabulsiIndividual7,886US$6.59
21 Jan 25SellUS$43,371Molly HendersonIndividual6,583US$6.59

Insider Trading Volume

Insider Buying: PHAT insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of PHAT?
Owner TypeNumber of SharesOwnership Percentage
Private Companies18,8490.0265%
Individual Insiders2,879,7394.05%
Hedge Funds5,081,4517.14%
General Public5,326,7867.49%
VC/PE Firms19,931,06228%
Institutions37,900,53453.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 81.1% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
17.5%
Frazier Life Sciences Management, LP
12,466,490US$202.5m0%5.31%
10.5%
Medicxi Ventures (UK) LLP
7,464,572US$121.2m0%14.83%
7.14%
Millennium Management LLC
5,081,451US$82.5m126%0.06%
4.95%
Invesco Ltd.
3,522,331US$57.2m-0.38%0.01%
4.92%
Abingworth LLP
3,496,808US$56.8m0%75.69%
4.78%
BlackRock, Inc.
3,402,324US$55.3m2.62%no data
4.52%
The Vanguard Group, Inc.
3,215,572US$52.2m15.4%no data
3.52%
Ensign Peak Advisors, Inc.
2,503,344US$40.7m-0.66%0.07%
2.76%
New Enterprise Associates, Inc.
1,960,169US$31.8m0%1.69%
2.56%
683 Capital Management, LLC
1,820,380US$29.6m-13.5%2.51%
2.16%
Wasatch Advisors LP
1,537,218US$25.0m5.15%0.09%
1.72%
David Socks
1,220,756US$19.8m0%no data
1.64%
Catalys Pacific
1,167,114US$19.0m0%6.32%
1.61%
GW&K Investment Management, LLC
1,144,330US$18.6m9.14%0.16%
1.59%
Catalio Capital Management, LP
1,128,521US$18.3m67.9%2.14%
1.53%
Geode Capital Management, LLC
1,088,910US$17.7m1.77%no data
1.48%
State Street Global Advisors, Inc.
1,053,591US$17.1m24%no data
1.31%
Azmi Nabulsi
929,335US$15.1m0%no data
0.84%
Moore Capital Management, LP
600,000US$9.7m0%0.21%
0.78%
Columbia Management Investment Advisers, LLC
554,590US$9.0m207%no data
0.78%
Propel Bio Management, LLC
552,927US$9.0m-40.1%9.98%
0.72%
Citadel Advisors LLC
508,720US$8.3m0%0.01%
0.6%
Aigh Capital Management, LLC
429,000US$7.0m0%2.1%
0.59%
Susquehanna International Group, LLP
422,239US$6.9m4.99%0.01%
0.59%
StepStone Group Inc.
422,085US$6.9m0%3.72%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/02 00:57
End of Day Share Price 2026/01/02 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Phathom Pharmaceuticals, Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jenna DavidnerBarclays
null nullBMO Capital Markets Equity Research
Kristen KluskaCantor Fitzgerald & Co.